---
layout: default
title: Acetaldehyde Alcaligenes Faecalis Candida Albicans
parent: 僅模型預測 (L5)
nav_order: 89
evidence_level: L5
indication_count: 0
---

# Acetaldehyde Alcaligenes Faecalis Candida Albicans
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Component Mixture (ACETALDEHYDE et al.): Insufficient Evidence for Drug Repurposing Evaluation

## One-Sentence Summary

This candidate is an 11-component mixture spanning microbial antigens, biological hormones, and botanical compounds, with no approved indications or market presence on record.
The TxGNN model did not generate any repurposing predictions for this candidate, and no supporting clinical or preclinical evidence was identified.
**A full repurposing evaluation cannot be conducted without resolving the identified data gaps.**

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | No record |
| Predicted New Indication | None — TxGNN returned no predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (below threshold — no predictions generated) |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

No TxGNN repurposing prediction was returned for this candidate, so the usual mechanism-to-indication reasoning cannot be applied. What can be said is that the composition itself raises significant identification challenges.

The candidate consists of 11 heterogeneous substances: acetaldehyde, *Alcaligenes faecalis*, *Candida albicans*, *Candida parapsilosis*, corticotropin human, coumarin, histamine dihydrochloride, L-lactic acid, quercetin, *Saccharomyces cerevisiae*, and *Sepia officinalis* juice. This profile — combining microbial antigens (gram-negative bacterium, multiple fungal species), a pituitary peptide hormone (corticotropin/ACTH), an immune mediator (histamine), and botanical/natural substances (coumarin, quercetin, cuttlefish ink) — is characteristic of homeopathic, isopathic, or allergen desensitisation preparations rather than a conventional small-molecule or biologic drug.

Without a DrugBank ID, an established mechanism of action, or any regulatory approval, it is not possible to meaningfully assess repurposing potential. The multi-component nature further complicates the attribution of any observed biological effect to a specific ingredient, making a standard TxGNN knowledge-graph mapping infeasible.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## US Market Information

This drug candidate has no regulatory approvals on record and is not currently marketed. No license data is available.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This 11-component mixture lacks a DrugBank ID, approved indications, TxGNN predictions, and any clinical or preclinical evidence; responsible repurposing evaluation requires resolving foundational data gaps before any development pathway can be assessed.

**To proceed, the following is needed:**

- **Identity clarification**: Confirm whether this combination corresponds to a single registered product (e.g., a homeopathic preparation) or a research-stage compound; obtain a DrugBank ID or equivalent regulatory identifier.
- **Mechanism of action (MOA)**: Document the pharmacological activity of each active component individually.
- **Regulatory anchor**: Determine whether any individual component holds standalone regulatory approval that could serve as the basis for a repurposing hypothesis.
- **TxGNN re-mapping**: Re-run predictions against each well-characterised individual ingredient rather than the full multi-component string.
- **Safety data**: Retrieve package insert warnings, contraindications, and drug interaction data (TFDA official monograph PDF) to enable S1 safety screening.
- **Data gap remediation**: Address DG001 (TFDA labelling/contraindications) and DG002 (MOA) as defined in the Evidence Pack before re-evaluation.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

